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ABSTRACT
Depression is a chronic disease which inflicts functional and emotional
impairment that has been a growing issue in the United States (US). Depression is the
most prevalent mental disorder in the US and is the leading cause of disability in the
world. By 2030, It is projected that major depressive disorder will be the second largest
contributor to global burden of disease. Causes of depression are still largely unknown
and treatments are often expensive, time consuming, and only available to certain
populations. Treatment often requires a combination of medicines and therapy to be
effective. In recent years, the gut microbiome has emerged as an important contributor to
a variety of cognitive functions. It has been demonstrated in many studies that a healthy
gut supports normal central nervous system function through the gut-brain axis. Clinical
studies have reported that the gut microbiota of depressed patients is significantly
different from that of healthy controls while some research has found that both the
microbiota diversity and richness was lower in depressed patients in comparison to
healthy controls. The microbiome is an emerging field of research with many of its
mechanisms and potential still unknown. The current study examined the associations
between urinary enterolignans (enterolactone and enterodiol) as a marker for gut
microbiome diversity and depressive symptoms in human subjects using the National
Health and Nutrition Examination Survey. The Patient Health Questionnaire-9 was used
for determining depression status of participants. We categorized urinary enterolignans
into quartiles using the distribution among the healthy, non-depressed participants and
iv

examined associations with depressive symptoms using survey logistic regression. The
study found that participants in the highest enterolactone quartile were less likely to be
experiencing depressive symptoms compared to those in the lowest quartile. While
associations between depressive symptoms and urinary enterodiol were generally inverse,
the effect estimates were weaker and none of the trend tests were statistically significant.
The results provide support for the hypothesis that gut microbiome diversity is inversely
related to depressive symptoms. These findings may lend support to intervention studies
aimed at altering the gut microbiota composition for improving psychological symptoms.
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CHAPTER 1
INTRODUCTION
Statement of Problem
Mental health problems are a growing concern in the United States (US).
Depression is the most prevalent mental disorder in the US with 17% of adults and 12%
of adolescents experiencing a depressive episode at least once in their lives. In the years
2009 through 2012, it was estimated that depression affected more the 5% of adults in the
US (Pratt et al., 2014). Depression is a chronic disease in which nearly all sufferers
experience functional impairment and two thirds of sufferers experience severe
impairment (Kessler et al., 2003). In fact, depression is the leading cause of disability in
the world (Murray et al., 2002). It is projected that by 2030, major depressive disorder
will be the second largest contributor to global burden of disease (Mathers, 2006). The
World Health Organization predicts depression will be the top cause of death by 2030
(Miret et al, 2013).
Physical impairments are associated with depression and it is shown that those
with depression have an elevated risk of morbidity and mortality. Depression can
aggravate existing heart conditions and is associated with an increased risk of stroke,
hypertension, and death after myocardial infarction (Lucas, 2018). Those affected by
depression are 11 times more likely to attempt suicide with more than one out of every
10 depressed individuals attempting suicide at some point in their lives (Kessler 1999,
Office of Applied Studies 2006).
1

Along with the emotional distress depression has on such a large population in
our society, it also has created a significant burden on our economy. In 2000 alone, major
depressive disorder cost $83.1 billion dollars (Greenberg et al, 2015). Of these 83.1
billion dollars, 31% were direct medical costs, 7% were suicide related mortality costs,
and 62% were workplace costs (Greenberg et al, 2015). Many who are afflicted with
depression are in greater need for primary and specialty care visits, utilize health services
more frequently, and are more likely to be hospitalized (Mojitabai,2001). It is estimated
that those with depression lose 5.6 hours of productivity per week due to their symptoms
(Stewart et al, 2003). This loss of productivity is seen in the 225 million workdays that
are missed and the equivocating $36.6 billion dollars in salary lost each year (Kessler,
2006). In addition, individuals with depression are twice as likely to be unemployed
compared to those who do not suffer from this disease (Mojitabai, 2001).
There has been a 37% increase in disability-adjusted life years of depression from
the year 1990 to 2010 (Murray et al, 2013). The percentage is likely to grow as the
condition becomes more prevalent each year. Currently, the effective remission rate of
antidepressants ranges from 60% to 80%, and the rate of favorable prognosis is
approximately 30% (Wilson et al, 2015). It is crucial that new strategies for treatment and
prevention are identified.
Risk Factors
Causes of depression are still largely unknown and treatments are often
expensive, time consuming, and only available to certain populations (McLaughlin,
2011). Often a combination of treatments is needed to manage depression (McLaughlin,
2011).
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Depression can be characterized as a neuroplastic, neurochemical, and
organization dysfunction of the brain (Falowski et al, 2011). There is also clinical
evidence that support the hypothesis that alterations in neuronal serotonergic and
noradrenergic function in the central nervous system is a cause of depression. (Nemeroff,
2002).
Depression is different with each person and can be a combined result of genetic
heredity and environmental influences (Sullivan et al, 2000). More recent studies have
found inflammation to be a contributing factor in depression through the activation of the
complement system and increased levels of inflammatory cytokines interleukin-6 (IL-6)
and tumor necrosis factor alpha (TNF-a) (Maes 1999, Berk et al, 2013).
Treatment
There is a wide range of treatment options for depression. Antidepressant drugs
are a common option for those with depression. It should be noted that only one-third of
depression patients exhibit beneficial results from drug treatment. While SSRIs (selective
5-HT reuptake inhibitors) and SNRIs (selective 5-HT norepinehphrine reuptake
inhibitors) are newer more effective treatments, they are expensive and often have
undesirable side effects that create new problems and difficulties for patients (Fournier et
al, 2009).
Cognitive behavioral therapy is another form of treatment commonly used as a
supplement for reducing depression-related symptoms. It is based on the premise that
inaccurate beliefs that form a basis for repetitive negative beliefs have a role in the
etiology of depression. Once the thinking is corrected, it is theorized that the symptoms
will be reduced (Hollon et al, 2010). However, studies have shown that there are
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disparities in the groups that benefit from cognitive behavioral therapy such as those with
chronic illness, poor sociodemographic status, and education levels having a poorer
response rate (Fournier et al, 2009). For this reason, naturopathic medicine has become a
major area of research for treating depression (Peng et al, 2015).
Microbiome
The human body is not only a host to its own cells but also 100 trillion bacteria
and 10 million microbiota genes known as the microbiome which is 10 times the number
of human body cells. There are an estimated 1,000 species and 7,000 strains of bacteria
residing on any given human (Kelly et al, 2016). The intestinal tract is one of the more
populated areas of bacterial concentration with nearly 1kg of bacteria, viruses,
protozoans, fungi, and arachaea inhabiting it (Latavola et al., 2017). The microbiome first
develops through vertical transmission from the placenta, amniotic fluid, and the
meconium (Gritz et al., 2015). The diversity of one’s gut microbiome varies greatly due
to differences in diet, environmental exposures, genetic diversity, and health status.
Despite the large difference between gut microbiomes, it is possible to distinguish
between them by examining the enterotypes populating them. Bacteroides, prevotella,
and ruminococcus are three species that can be observed to determine the type of diet a
person is largely consuming. By examining a person’s gut microbiome, much
information about their health and health practices can be determined (The Human
Microbiome Project Consortium, 2012).
Stress, diet, and medications are all reasons why an individual’s gut microbiome
could be altered. When a microbiome is altered resulting in dysbiosis, a number of health
outcomes can occur. When dysbiosis occurs, there is an increase in intestinal
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permeability which allows bacteria and their metabolites to enter into the systemic
circulation. This also is known as leaky gut syndrome which illustrates how the gut, when
in dysbiosis can have major health implications to humans (Clapp et al., 2017). Research
on the gut microbiome has exploded in recent years with the advent of the Human
Microbiome Project which has assessed microbiota in 15-18 body sites (Human
Microbiome Project Consortium, 2012).
Gut Brain Axis a Mechanism for Depression
It has been illustrated in many studies that a healthy gut supports normal central
nervous system function (Daulatzai, 2015). The mechanism backing this claim is known
as the gut-brain axis (GBA). The gut-brain axis is the bidirectional communication
between the gut microbiota and the central nervous system (Clapp et al., 2017). The
intestinal tract is controlled by both intrinsic and extrinsic nerves. With 200-600 million
nerves, the gut is known as the “second brain” (Gershon, 1999). The vagus nerve is
primarily responsible for conveying messages between the gut and the brain (Anglin et
al., 2015). The microbiota can release multiple different neurotransmitters which are
capable of regulating nerve signals. These nerve signals affect a variety of
neuropsychiatric parameters such as mood and cognition (Kali et al, 2016). Inflammation
of the gastrointestinal tract can cause dysbiosis as a result of the release of cytokines and
neurotransmitters. When these molecules are able to enter the body systemically via the
leaky gut, the blood brain barrier then exhibits permeability. Brain function is then
altered which could lead to symptoms of anxiety and depression (Gadek et al. 2013,
Biesman et al, 2015).
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Lipopolysaccharides (LPS) are another example of a proinflammatory endotoxin
released during an inflammatory response. There is usually only a small amount of LPS
in the gut because of the intestinal barrier. However, when a leaky gut is present LPS can
enter the blood stream resulting in its ability to regulate the neural system increasing the
activity of the amygdala which in turn affects emotion. One study showed that humans
given LPS had inflammatory cytokines released, and an increase in circulating
norepinephrine occurred which is linked to high depression mortality (Magniola et al.,
2016). Even a relatively small increase in LPS is associated with acute anxiety and
depression (Bested et al., 2013). Thus, there is ample biologic evidence to suggest that
the composition of the gut microbiota may impact depression. However, given the
relatively few studies that have collected stool samples in human populations in which
depression data also are available, there is a need for more human studies examining
associations between gut microbiome diversity and depression.
Specific Aims and Proposal
The aim of this thesis was to examine the association between gut microbiome
diversity and depression using the National Health and Nutrition Examination Survey
(NHANES). We used urinary enterolignans (enterolactone and enterodiol) measured on a
continuous scale as a marker for gut diversity. Severity of depressive symptoms as
assessed by the Patient Health Questionnaire (PHQ-9) was used as an indicator for
depression and was scored as a categorical variable.
Significance of Research
Depression is an extremely prevalent disease that has major negative impacts on
not only an individual but also the nation’s productivity. Current treatments do little to
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help those suffering with depression cope with their illness and often have undesirable
side effects. Drugs for depression are expensive and usually are not obtained until after
several consultations and doctors’ visits. Because a person’s microbiome is largely
dependent on what they eat, making dietary changes and fostering a healthy microbiome
could be a nonpharmaceutical safer approach to treating symptoms of depression thus
potentially cutting spending on expensive treatments and healthcare costs.
The microbiome is an emerging field of research with many of its mechanisms
and potential still unknown. Over 90% of the more than 4,000 articles on microbiota were
published in PubMed from 2010-2015 (Khanna et al 2014). We examined the
associations between urinary enterolignans (enterolactone and enterodiol) as a marker for
gut diversity and depression in human subjects.
If an increased microbial diversity is associated with a decreased risk of
depression, it could indicate an area of research that needs to be more closely explored to
identify the mechanism by which this is occurring and represents a new target for
intervention to treat or prevent depression.
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CHAPTER 2
LITERATURE REVIEW
Microbiome Diversity
Eighty percent of the 100 trillion bacteria, fungi, viruses and other
microorganisms that exist as human microflora are found in the gut. The two bacteria
phyla that account for 70-75% of the gut microbiome are Bacteroidetes and Firmicutes.
Some of the other bacteria commonly found in the gut, though in smaller quantities, are
Proteobacteria, Actinomyces, Fusobacterium, and Verrucomicrobia (Diamant et. al,
2011). The microbiota in our guts play multiple roles. The gut microbiome acts as an
intestinal barrier, promotes the continuous existence of gut microbiota, stimulates
intestinal epithelial cell regeneration, synthesizes vitamins, and produces mucus and
nourishes mucosa by producing short-chain fatty acids (SCFAs) (Burger-van Paassen et
al, 2009). At birth, humans have an innate immune system that the gut microbiome
stimulates and helps mature large parts of the intestinal lymphoid tissue and helps
develop acquired immunity by stimulating local and systemic immune responses (Nell et
al., 2010). Under various physiologic conditions, the gut can continuously stimulate the
immune system which creates low level inflammation in the body which is typically done
to fight off pathogens (Rakoff-Nahoum, et al., 2004).
Healthy Gut Diversity
Clinical studies have reported that the gut microbiota of depressed patients is
significantly different from that of healthy controls (Kelly et.al, 2016 Zheng et al, 2016).
8

Some research found that both the microbiota diversity and richness was lower
among depressed patients in comparison to healthy controls. In a study where the fecal
microbiota of depressed individuals was compared to control individuals, depressed
individuals were shown to have a lower richness and diversity (Kelly et. al, 2016). The
depressed group also had increased levels of the inflammatory cytokine IL-6. Fecal
microbiome transplantations were performed from depressed humans to germfree rats.
These rats where shown to develop behavioral and physiological features of depression
post-transplant. These rats also experienced a reduction in richness and alpha diversity
(Kelly et. al, 2016). Similar results were found in a study that transplanted the gut
microbiome of a patient with major depressive disorder (MDD) to rats. Fecal samples
collected from depressed and nondepressed individuals showed depressed individuals had
less Bacteroidetes than those without depression (Zheng et al., 2016).
Human and animal studies alike have shown probiotics’ ability to reduce
symptoms of anxiety and depression. Probiotics are often used to increase gut
microbiome diversity and foster a stable gut environment free from dysbiosis. One study
provided human patients with chronic stress a three-week probiotic treatment that
contained Bifidobacterial species. The subjects who scored as depressed in the
elated/depressed scale showed improvement in mood with these supplements (Benton et
al, 2007). Another double blinded clinical trial tested the effectiveness of probiotics on
depression with both rats and humans. The human study gave participants either a
placebo or a probiotic in a 30-day trial. Of the 66 participants that entered, 55 completed
the study. Participants were Caucasian males and females ages 30-60 years. Depression
was measured using the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety
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and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL)
and 24 h urinary free cortisol (UFC). The participants given probiotics had reduced
urinary cortisol levels and improved psychological effects to a similar magnitude as those
on the antidepressant. The 36 male rats were either given diazepam, probiotics, or a
placebo. The reduction in stress/anxiety score were statistically significantly reduced for
the probiotic and diazepam group compared to the placebo group (p-value 0.001)
(Messaoudi et al., 2011). The results of these studies have public health relevance
because probiotics are easily accessible to people through either capsules or those that
naturally occur in foods like yogurt and kefir (Sehlub et al, 2014). A summary of the
studies related to the gut microbiome and depression in humans is provided in Table 1.0.
Inflammation and Dysbiosis
When the gut microbiome undergoes stressors such as changes in diet,
medications, or stress, the composition of the microbiome changes. Many diseases that
are prevalent in Westernized countries are associated with dysbiosis and a loss of gut
microbial diversity (Mosca et al, 2016). Loss of microbial diversity is a common feature
in dysbiosis. Much of the Western lifestyle can explain why the US is shown to have
lower gut diversity compared to other lesser developed countries (Mosca et al, 2016).
Diets high in processed foods and low in fiber are unable to provide many of the healthy
gut bacteria with enough nutrients to survive (Mosca et al, 2016). When the gut
microbiome is in a dysbiotic state, there is an increase in intestinal permeability which
allows bacterial metabolites and even bacteria themselves to leak into systemic
circulation (Clapp et al.,2017). This contributes to chronic low-grade inflammation which
can be observed in patients with depression. Chronic low-grade inflammation in the gut
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has been associated with several subgroups of depressive disorders (Dantzer et al, 2008).
Both internal and external factors can cause inflammation in the body. When
inflammation appears in the gastrointestinal tract, cytokines and neurotransmitters are
released. With the increase in intestinal permeability, the cytokines can travel
systemically through the body. When the blood carries higher levels of cytokines such as
TNF-a and monocyte chemoattractant protein, there is then a permeability in the blood
brain barrier which allows these inflammatory cytokines to influence the brain (Gadek et
al, 2013).
Gut-Brain Axis Pathways
The gut-brain axis is the bidirectional communication between the gut and the
brain (Cryan et al., 2012). Gut bacteria can affect the cognitive functions of the brain
(Jenkins et. al, 2016, Schmidt et al 2015). There is still much to be understood about the
gut-brain axis but there are a few proposed pathways theorized. Some pathways from the
gut microbiota include the neuroanatomical pathway of gut-brain axis, neuroendocrine
hypothalamic–pituitary–adrenal axis (HPA axis) pathway, gut immune system, gut
microbiota metabolism system, and intestinal mucosal barrier and blood brain barrier
(Wang et al, 2016). Disruption in the gut microbiome/reduced diversity could offset any
of these pathways (Wang et al, 2016).
Neuroanatomical Pathway of Gut-Brain Axis
Two neuroanatomical pathways the gut uses to interact with the brain are the
autonomic system/vagus nerve and the enteric nervous system. The enteric nervous
system is in the gut while the autonomic nervous system and vagus nerve are in the spine.
The vagus nerve provides a direct link between the gut and the brain. Bacteria can
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stimulate the afferent neurons in the enteric nervous system which signals the vagus
nerve to induce either an anti-inflammatory or pro-inflammatory response. The most
important effect of the dorsal motor nucleus of the vagus nerve is prominent in the upper
gastrointestinal tract, and the cholinergic neurons on myenteron of upper gastrointestinal
tract regulate vagal excitability effect (Chang et al, 2002).
Neuroendocrine HPA axis pathway
Gut bacteria are responsible for much of the hormone synthesis in the body.
Dopamine and serotonin are synthesized in the gut which can directly influence the brain
(Galland, 2014). Some bacterial enzymes in the gut are responsible for releasing
neurotoxins as their byproducts which also can directly affect the brain (Galland, 2014).
Lacking gut microbiota and low/lack of expression of toll-like receptors (TLRs)
contribute to producing a neuroendocrine response to the pathogens in the gut (O’hara et
al., 2002). Some studies have shown that the HPA axis can be activated by the gut
microbiome when there is increased permeability of the intestinal barrier due to an
inflammatory environment. Stress induces endotoxemia and low-grade inflammation by
increasing barrier permeability (de Punder et al., 2015). Gut microbiome development in
early stages of life have been recognized to influence later brain function and behavior
including neuroendocrine responses to stress (O’Mahony et al., 2017).
Gut and the immune system
Approximately 70–80% of the body's immune cells are contained within the gutassociated lymphoid tissue. Development of the immune system depends on gut
microbiota (Mayer et al., 2015). While germ-free mice showed no immune activity,
immune function could be produced when they were introduced to various microbes.
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Lack of a gut immune system as a result of a germ-free environment has been shown to
exemplify anxiety behaviors in multiple animal studies. Central nervous system
neurotransmission can be disrupted through dysbiosis (Heijtz et al.,2011, Neufeld et al.,
2010). Because the gut microbiome can induce an inflammatory response, it may also be
involved in the regulation of emotion and behavior (Forsythe et al., 2010).
Gut microbes also metabolize bile acids and amino acids to produce other
chemicals that affect the brain (Clarke et al., 2013). There is more than 100 times more
genetic information in the human microbiome than the human genome. There are genes
that encode proteins for metabolic functions that produce metabolites only found in the
microbiome. These metabolites can affect the gastrointestinal environment and the gut
wall and can reach the brain if they are absorbed into the systemic circulation (Clarke et
al., 2014).
Urinary Enterolignans
Enterolignans (enterolactone and enterodiol) are metabolic byproducts of lignans,
polyphenolic compounds found in plant foods such as grains, legumes and seeds. The gut
has many microorganisms that are capable of digesting lignans which makes it the
primary location for lignan metabolism. High urinary enterolignan concentrations can
provide a marker of a microbial environment capable of biotransforming lignan
precursors. In a cross-sectional study using human stool samples, gut microbiome
diversity was positively related to urinary enterolactone levels but was not substantially
associated with urinary enterodiol levels (Hullar et al., 2014). Both alpha- and betadiversity were higher among subjects with high enterolactone excretion. Dietary intake is
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also related to enterolignan excretion, with fiber intake being especially highly correlated
with urinary enterolignan levels (Hullar et al. 2014).
Urinary enterolignan concentrations have been used as a marker for gut
microbiome diversity in studies using NHANES data previously. One study reported that
a more pro-inflammatory diet (as assessed by the Dietary Inflammatory Index) was
associated with lower concentrations of urinary enterolignans, and hence, lower gut
microbiome diversity (Shivappa et al, 2019). Urinary enterolignan data from NHANES
also was used as a marker for gut microbiome diversity when examining the relationship
between gut microbial environment and obesity (Frankenfeld et al., 2013). Currently,
NHANES does not directly measure gut microbiota composition, such as by 16s rRNA
sequencing methods or metagenomics, thus, urinary enterolignans are used in the current
study as an indirect marker for gut microbiome diversity.
Potential Confounders
Antibiotics
The effects of antibiotics on microbial diversity has been heavily researched.
Humans are exposed to antibiotics not only as medications but also in many of the foods
consumed as antibiotics are often used in farming (Department of Agriculture, 2006).
Broad spectrum antibiotics can affect the diversity of bacteria in a gut microbiome,
reducing diversity by 30% (Dethlefesen et al., 2011). Currently, microbial resistance in
human populations has led to concerns about overprescribing of antibiotics (FlemingDutra, 2016). One study used the National Ambulatory Medical Care Survey and
National Hospital Ambulatory Medical Care Survey to assess antibiotic use trends
(Fleming-Dutra, 2016). They defined an antibiotic prescription to be “unnecessary” based
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on national guidelines and regional variation in prescribing. The diagnosis-specific
prevalence and rates of total and appropriate antibiotic prescriptions were determined
(Fleming-Dutra, 2016). Thirty percent of the 154 million antibiotic prescriptions filled
each year were determined to be unnecessary (Fleming-Dutra, 2016) Forty-four percent
of the outpatient antibiotic prescriptions were written to treat many respiratory conditions
(Fleming-Dutra, 2016) with nearly half of these outpatient prescriptions determined to be
unnecessary (Fleming-Dutra, 2016). The gut microbiome can recover from antibiotic
exposure, but it often takes months or years (US Department of Agriculture, 2008).
There are theories that humans ingest antibiotics through the consumption of
animal products. Because livestock are often raised in close quarters, safety measures
must be taken to manage infections that can be spread from animal to animal. Antibiotics
are used to treat many of the infections common among livestock. They are also used to
increase animal growth (McEwen et al., 2002). Nearly 16% of lactating cows in the US
receive antibiotics for acute infections. However, almost all dairy cows receive
antibiotics following lactation to prevent the spread of infections (McCluskey, 2003).
Almost 15% of calves receive antibiotics for acute infections while 10% of non-infected
calves receive antibiotics for preventive measures (Dargatz, 2000). Around 88% of swine
receive antibiotics as disease prevention and growth promotion (Dargatz, 2000).
Maurice et al. found in their laboratory study that antibiotics can alter the
physiological state and activity of the gut resulting in an increased number of damaged
membranes and a decrease in the number of active populations of bacteria. A number of
genes involved with antibiotic resistance and stress response also were increased in
expression as a result of antibiotic exposure (Maurice et al., 2012). When gut microbiome
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diversity is inhibited, opportunistic bacteria have a greater chance at being able to
flourish such as C. Difficile. In one study, early antibiotic exposure reduced the diversity
of a child’s microbiome and altered its composition (Tanaka et al., 2017).
Antibiotic use has been linked to depression in one study. A single antibiotic
course of treatment was associated with a higher risk for depression [adjusted odds ratio
(AOR) of 1.23 for penicillins (95% confidence interval (CI), 1.18-1.29) and 1.25 (95%
CI, 1.15-1.35) for quinolones]. The risk increased with recurrent antibiotic exposures to
1.40 (95% CI, 1.35-1.46) and 1.56 (95% CI, 1.46-1.65) for 2-5 and > 5 courses of
penicillin (Lurie et al., 2015). Thus, recent antibiotic use may be an important factor to
consider in the relationship between gut diversity and depression.
Oral Steroid Use
While some steroids are use to treat gastrointestinal disorders such as Crohns,
they also can increase the risk of other disorders such as ulcers due to the alteration in
mucosal lining they can cause (Huang et al, 2015). When oral steroids are taken, gut
bacteria has been shows to be responsible for keeping an anti-inflammatory environment.
When the mucosal layer is damaged, inflammation increases and gut dysbiosis is more
likely to occur (Huang et al, 2015).
Age
The composition of a microbiome varies greatly by age. An infant has a very
different microbial composition compared to a young adult. Illness, medication use, and
diet are some key components that explain why the gut microbiome changes over time.
Langille et al. observed a statistically significant difference in taxonomic patterns in the
gut microbiomes of young, middle, and old mice (Langille et al., 2014).
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Similarly, gut flora clustering patterns were shown based on different age ranges,
generally decreasing in diversity in samples of older individuals. Common to all age
groups were the Bacteroidaceae, Lachnospiraceae, and Ruminococcaceae families.
However, their abundance decreased as age increased (Yatsuneko et al., 2012).
Body Mass Index
Bacteroidetes and Firmicutes are two of the more dominating beneficial bacteria
in the human gut microbiome. In a study done by Ley et al., the proportion of
Bacteroidetes was lower in obese people compared to those who were lean. Weight loss
and low-calorie diets were shown to reverse this disproportion (Ley et al.,2006).
Turnbaugh et al. similarly found that the microbiome associated with a greater body mass
index (BMI) had a greater capacity to harvest energy and that when lean mice were
colonized with this microbiome, they gained a significantly greater body weight. Obese
mice that were colonized with the lean microbiota lost weight (Turnbaugh et al., 2006).
Obesity is also one of the most common comorbidities of depression (De Wit et
al., 2010). The temporality of the association is complex, as it has been reported that
obesity can increase the risk of depression while depression can increase the risk of
obesity (Luppino et al., 2010).
Gender
Women are nearly twice as likely to be depressed compared to men (American
Psychiatric Association, 2013). This gap is apparent in all socioeconomic groups.
Hormonal differences and differences in HPA axis activation levels are some proposed
theories for this disparity. Women also experience different interpersonal environmental
exposures than men (American Psychiatric Association, 2013, Kuehner, 2017).
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Alcohol
When comparing alcoholics to a control group, chronic alcohol abuse has been
shown to change the bacteria composition in the gut. This dysbiosis was correlated with
high levels of serum endotoxin (Mutulu et al., 2012). Chronic alcohol abuse has been
shown to lead to small intestinal bacterial overgrowth resulting in dysbiosis.
Some of the highest rates of depression are among those who abuse alcohol.
Research has shown that anywhere between 30-50 percent of people who abuse alcohol
experience depressive symptoms. One household survey found that 16% of those with
depression had an alcohol diagnosis (Bode et al., 1984). Those with depression were
found to have a 30% lifetime alcohol problem (Lynn et al., 2005).
Smoking
Smoking has been explored as an environmental factor that can alter the human
gut microbiome community. In a clinical trial by Beidermann et al., gut microbiome
composition was analyzed with smoking cessation. Diversity in those who quit smoking
was significantly higher than their baseline measurements. After 8 weeks the trend
continued, and microbiome diversity increased. Those in the control group who did not
quit smoking showed the same levels of diversity throughout the study (Biedermann et
al., 2013). In another human study, gut microbial diversity was assessed in Crohn’s
disease patients who smoked vs nonsmokers. Gut microbial gene richness, gene diversity,
and species diversity was decreased in abundance among smoking participants along with
other genera (Opstelleleten et al.,2016).
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While it is unclear why smoking is more prevalent among those with mental
health issues there is a clear association between depression and smoking. For every ten
cigarettes smoked in the US, three are smoked by someone with a mental illness (CDC,
2013).
Socioeconomic Status
Socioeconomic status (SES) has been shown to be associated with risk for
depression. Nationally representative data found a significant association between
depression and SES (p-value <0.0001) across multiple countries. As SES increased,
depression decreased (Freemen et al., 2016). An increasing amount of evidence shows
that purchasing and consumption of unhealthy diets and also eating fewer fruits and
vegetables is strongly associated with socioeconomic status. Those with lower SES have
been shown to have a lower quality diet compared to those with a higher SES (Appelhans
et al., 2012, Darmon and Drewnowski, 2008). Therefore, those with lower SES are less
likely to have a varied and healthy diet that would foster a diverse gut microbiome.
Race
Depression rates have been reported to vary by race (Dunlop et al., 2013).
Minorities usually present higher rates of depression compared to whites. Minorities
more often have greater health burdens and a lack of health insurance (Dunlop et al.,
2013). Using population based national data, one study found African Americans OR =
1.16, 95% CI= 0.93, 1.44) and Hispanics (OR = 1.44, 95% CI = 1.02, 2.04) had higher
rates of major depression compared to whites (Dunlop et al., 2013). Studies have shown
that gut microbiome diversity differs between races globally and across races in the US
(Gupta et al.,2017, Brooks et al., 2018), likely related to ancestry of various races and
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cultural and lifestyle differences (Gupta et al.,2017, Brooks et al., 2018). Western
societies were shown to have the lowest gut diversity compared to foraging or
agricultural societies (Gupta et al., 2017). Brooks et al. used data from the American Gut
Project to analyze microbiome differences among Hispanics, Whites, Pacific Asians, and
African Americans living in the US. Subtle but significant differences were found in
taxonomic composition between four ethnicities (Brooks et al.,2018).

20

Table 2.1 Summary of Studies Related to Gut Microbiome Diversity and Depression
Author,
yr

Study Design

Country

Sample
Size

Outcome

Exposure

M.
Soledad
Cepeda,
2016

Cross
sectional

United
States

18,090

Patient
Health
Questionna
ire scores
≥10

Any
probiotic
food or
supplement

Confounders/
Effect
modifiers
age, gender
race/ethnicity,
overall health,
lifestyle, and
socioeconomi
c status

Results

The overall prevalence of mild or
more severe depression was
22.80% (PHQ-9 ≥5) and 7.59%
for moderate or more severe
depression (PHQ-9 ≥10). Subjects
exposed to probiotics were less
likely to have depression.
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After adjustment, the association
between probiotic exposure and
depression disappeared.

Benton,
2007

Kelly,
2017

A doubleUnited
blind placebo- Kingdom
controlled
trial with
random
allocation of
subjects.
Clinical Trial Ireland

132

Profile of
mood state
questionnai
re assessed
mood

34
depressed
patients
and 33
healthy
patients

Alterations
in
depression
using
levels of
SCFA

A
probioticcontaining
milk drink
and a milkbased
placebo
Alterations
in the gut
microbiota
compositio
n in
patients

No general effects of taking the
probiotic were found when daily
mood ratings were considered.

Education
level,
employment
status,
smoking and

Depression is associated with an
altered gut microbiota
composition, richness and
diversity. Richness and diversity
was lower in depressed patients.

Zheng,
2016

Clinical
Experiment

Verdam,
2013

Clinical
Experiment

China

58 major
depressiv
e disorder
patients
and 63
healthy
controls
Netherlan 28
ds

Gut
microbial
communiti
es from
fecal
samples

with
depression
Depression
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Fecal
Obesity
microbiota
compositio
Fecal
calprotectin
and plasma
C-reactive
protein
levels

alcohol
consumption.
age and body
mass index
were
controlled for

Exclusion if
subjects
received
antibiotics in
the last 6
months, used
anti‐
inflammatory
drugs, or
reported
alcohol
consumption
>63 g/week.
Other
exclusion
criteria were
acute and
chronic
inflammatory
diseases

Compared with healthy controls,
the relative abundances of
Actinobacteria were increased in
MDD subjects, while those of
Bacteroidetes were decreased

Obese participants showed
reduced bacterial diversity, a
decreased
Bacteroidetes/Firmicutes ratio,
and an increased abundance of
potential proinflammatory
Proteobacteria. Interestingly,
fecal calprotectin was only
detectable in subjects within the
obese microbiota cluster. Plasma
C-reactive protein was also
increased in these subjects and
correlated with the
Bacteroidetes/Firmicutes ratio

Luries,
2015

Nested Case
Control

United
Kingdom

202,974

Risk for
depression,
anxiety, or
psychosis

Therapy
with 1 of 7
antibiotic
classes > 1
year before
index date

obesity,
smoking
history,
alcohol
consumption,
SES, and
number of
previous
urinary tract
and upper and
lower
respiratory
infections

Treatment with a single antibiotic
course was associated with higher
risk for depression with all
antibiotic groups. The risk
increased with recurrent antibiotic
exposures to 1.40 (95% CI, 1.351.46) and 1.56 (95% CI, 1.461.65) for 2-5 and > 5 courses of
penicillin.
Recurrent antibiotic exposure is
associated with increased risk for
depression and anxiety but not for
psychosis.
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CHAPTER 3
RESEARCH METHODS
To accomplish the specific aims, we utilized cross-sectional data from NHANES,
including multiple waves (2005-2006, 2007-2008, and 2009-2010). The data are deidentified and freely available to the public and thus deemed exempt from IRB approval.
NHANES is a cross-sectional survey with multiple stages that is produced by the
National Center for Health Statistics. The goal of the NHANES survey is to measure the
health and nutrition status of both children and adults in the US. The NHANES survey is
administered every two years to collect a nationally representative depiction of the health
of the United States. The study population for the project was restricted to 2005-2006,
2007-2008, and 2009-2010 NHANES survey data with no missing data on any
covariates. We excluded subjects who reported oral antibiotic or oral steroid use within
the past 30 days. Years were chosen based on when urinary enterolignans were measured
and PHQ-9 was used in NHANES along with the other covariate measures.
Main Exposure: Urinary Enterolignans as a Marker for Gut Diversity
Enterolignans (enterolactone and enterodiol) were measured in spot urine
samples. Urine samples were collected the morning after a fast by agreeing participants
and the samples were stored at -20C until they were processed and shipped to the
Division of Laboratory Sciences, National Center for Environmental Health, Centers for
Disease Control and Prevention to be analyzed. High performance liquid
chromatography–atmospheric pressure photoionization–tandem mass spectrometry
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(HPLC–APPI–MS/MS) was used for the quantitative detection of enterolactone and
enterodiol. Human urine samples were processed using enzymatic deconjugation of the
glucuronidated phytoestrogens followed by size-exclusion filtration. Phytoestrogens were
then separated from other urine components by reversed-phase HPLC, detected by APPI–
MS/MS, and quantified by isotope dilution. Assay precision was improved by
incorporating carbon-13 labeled internal standards for each of the analytes, as well as a 4methylumbelliferyl glucuronide and 4-methylumbelliferyl sulfate standards to monitor
deconjugation efficiency (Geinstein, 2010). Creatinine values were used to account for
urine dilution. To do this, each individual’s enterolignan concentration value (ng/ml) was
divided by the corresponding urinary creatinine value (mg/dL) and standardized to ug/g
units (Shippava et al., 2019). We categorized urinary enterolignans into quartiles using
the distribution among the healthy, non-depressed participants.
Primary outcome
Depression was measured in NHANES with the Patient Health Questionnaire
(PHQ-9). The PHQ-9 is a 9-item depression screening instrument that asks participants to
choose one of four responses about frequency of depressive symptoms during the
previous 2 weeks. NHANES has been using the PHQ-9 since 2006 and it can be used to
assess major depression and depression severity. There are nine items on the examination
with a final follow up question regarding overall impairment of the depressive symptoms.
The responses for the nine questions range from “not at all”, “several days”, “more than
half the days” and “nearly every day.” These were scored 0-3. The test is administered by
trained interviewers using a Computer-Assisted Personal Interviewing System as part of
the private interview in English or Spanish. No proxies or interpreters are allowed for this
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examination. The exam allows for a maximum score of 27 and a minimum score of 0
(CDC, 2013). Two different methods were used to create the dichotomous outcome. The
Pfizer method classified a participant as depressed if a participant marks 2-4 questions as
a level 2 or 3 response (one of which corresponds to the first or second question in the
survey). Those not meeting this criterion were categorized as not having depressive
symptoms. In the Kroenke method, subjects are classified as having depressive symptoms
if PHQ-9 scores are greater than or equal to 10. In their study, a cut point of 10 was
shown to be 88% sensitive in identifying participants with a depressive disorder (Kroenke
et al., 2001). In exploratory analyses, we also used the method by Pfizer which creates a
three-level outcome. A total score of 0-4 is minimal depression, a score of 5-14 is
moderate depression, and a score greater than 15 is severe depression (Cepeda et al.,
2017).
Confounders
Antibiotic and Steroid Use
NHANES collects data on prescription medications used in the past 30 days. This
is done through direct abstraction from prescription medication containers. During the
household interview, respondents aged ≥16 years were asked: ‘In the past 30 days, have
you used or taken medication for which a prescription is needed?’ For respondents under
the age of 16 or those that could not respond to the question, a proxy responded. Those
who answered affirmatively were asked to give their prescription medication containers
to the interviewer and report details of its use. The participant verbally reports
medications used if the container is not available.
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The drug names reported were converted into a generic drug name for the data
release and a therapeutic drug class was assigned based on the Multum Lexicon Drug
Database. A dichotomous variable was created to indicate whether a participant had taken
an antibiotic in the past 30 days by examining the first level category ‘anti-infectives’.
Subjects who reported using an antibiotic within the past 30 days were excluded from
analyses. Topical antibiotics were not excluded (Kantor et al, 2015). Anyone who had
taken prednisone, prednisolone, methylprednisolone, or methylprednisolone acetate was
marked as positive for taking an oral steroid in the past 30 days and was then excluded
(Sversky et al., 2011,).
Laxatives/Stomach Illness
Any participant who had reported taking a laxative before their laboratory testing
or reported having a stomach illness in the past 30 days were excluded.
Alcohol Use
Alcohol was measured by the self-reported average number of alcoholic drinks
consumed each day over the previous year (continuous variable).
Smoking
Smoking data were self-reported by the subjects in response to the following
questions: Have you smoked at least 100 cigarettes during your entire life?; Do you
smoke cigarettes now?; On the average, how many cigarettes a day do you smoke?; How
long has it been since you smoked cigarettes fairly regularly?; During the period when
you were smoking the most, about how many cigarettes a day did you actually smoke?;
and About how old were you when you first started smoking cigarettes fairly regularly?
Nonsmokers were defined as: never smoked 100 cigarettes and does not smoke cigarettes
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currently. Former smokers included recent former smokers (quit smoking cigarettes
during the year prior to interview), and longer-term former smokers (quit smoking
cigarettes more than one year prior to interview. Categories include never smoker, former
smoker, and current smoker. Current cigarette smokers were categorized by pack years;
0-10, 11-20, and >20. Former smokers were categorized by how long ago they quit
smoking; <10 years or >10 years.
Gender
The variable gender in the NHANES dataset is a self-reported measure having the
value male or female.
Age
Age is a self-reported measures and continuous variable.
Body mass index (BMI)
BMI values are calculated for NHANES participants using measured height and
weight values as follows: weight (kilograms)/height (meters) 2. BMI criteria were used to
screen for weight categories: underweight (BMI values < 18.5), normal or desirable
weight (BMI values 18.5-24.9), overweight (BMI values 25.0-29.9), obese (BMI values
greater than or equal to 30) (National Institutes of Health, 1998).
Race
Races is a self-reported measure and is a categorical variable: Mexican American,
Non-Hispanic White, Non-Hispanic Black, or Other Race.
Poverty Index Ratio (PIR)
Poverty level index (INDFMMPI) was then grouped into three categories (i.e.,
INDFMMPI ≤1, 2 < INDFMMPI ≤ 4; INDFMMPI >5.
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Marital Status
Marital status is a self-reported measure and a categorical variable: single,
married, widowed, or separated/divorced.
Education
Education is a self-reported measure and a categorical variable: Less than 9 th, 911 grade, high school, some college, or greater than college.
Missing Data
Any participants missing outcome, covariate, or exposure data were not included
in the final analyses.
Statistical Analyses
NHANES uses a complex survey design which requires the use of sample weights
to create a representative US population. Environmental 2-year weights provided for the
phytoestrogen data were utilized. Using the estimation procedure guidelines provided by
NHANES, we multiplied the weight variable by 1/3 because we included three survey
periods. (National Center for Health Statistics 2007). All statistical analyses were
completed using SAS 9.4.
A complex survey design was used to analyze the association between urinary
enterolignans and depression. We first ran a simple survey logistic regression model for
the main exposure and outcome variables. We then used survey logistic regression
models to calculate the OR and 95% CI for the association between urinary enterolignan
levels and depression while controlling for potential confounders listed above. Covariate
selection was chosen based on the literature supporting their association with both gut
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diversity and depression. The p for trend was calculated using the continuous urinary
enterolignan variable in each of the models.
We hypothesized that higher urinary enterolignan levels would be associated with
lower odds of depressive symptoms. We ran the analysis with urinary enterolignan levels
being categorical variables (quartiles) using cut points based on the control (nondepressed) population. We used the lowest urinary enterolignan quartile as the referent
group in logistic regression analyses.
Depression was coded as a dichotomous outcome with two different scoring
methods. Using the Kroenke method, subjects are classified as having depressive
symptoms if PHQ-9 scores were greater than or equal to 10. Those less than 10 was
classified as not having depressive symptoms. Using the Pfizer method, a participant who
marks 2-4 questions as a level 2 or 3 response (one of which corresponds to question 1 or
2) was categorized as having depressive symptoms. Those not meeting this criterion were
categorized as not having depressive symptoms.
In exploratory analyses, we also ran a survey logistic regression model utilizing a
three-level outcome variable where a total score of 0-4 is minimal depression, a score of
5-14 is moderate depression, and a score greater than 15 is severe depression. Three
separate survey logistic regression models were run; minimal depression vs severe
depression, minimal depression vs moderate depression, and moderate depression vs
severe depression. (Cepeda et al., 2017). To examine whether the association between
urinary enterolignans and depression is modified by certain covariates (specifically age,
gender, smoking status, BMI, and race), we stratified on the a priori chosen categorical
covariates.
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CHAPTER 4
RESULTS
Tables 4.1-4.3 Descriptive Statistics
Participants missing data on enterolactone concentration, enterodiol
concentration, PHQ-9 scoring, and/or any of the covariates were excluded. The final
sample consisted of 1,933 subjects (Figure 4.1). These tables represent raw sample sizes.
When conducting the analysis, weighted means and frequencies were utilized for
descriptive purposes. When using the Pfizer dichotomous outcome scoring method, 1,712
participants were not depressed and 221 had depressive symptoms. When using the
Kroenke dichotomous outcome scoring method, 1,739 participants were not depressed,
and 194 participants had depressive symptoms. When categorizing depression as a threelevel outcome, 1,314 had minimal depression, 554 had moderate depression, and 65 had
severe depression. In all three scoring methods, average enterolactone and enterodiol
concentrations were lower in the depressed groups when compared to the non-depressed
counterparts. In each scoring method, a greater percentage of females where in the
depressed categories.
Table 4.4 Reference Ranges
Enterolignan quartile cutpoint values were determined by using the distribution of
urinary enterolignan concentrations of the non-depressed group in each scoring method.
The ranges for the quartile cutpoints are provided in Table 4.4.
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Table 4.5 Main Effects in Dichotomous Outcome – Pfizer
When using the Pfizer method for categorizing the dichotomous outcome
variable, an inverse association between urinary enterolactone and depressive symptoms
was observed in the simple model (ORQ4vsQ1: 0.39, 95% CI: 0.19-1.02) which was
slightly attenuated after adjustment for multiple covariates (ORQ4vsQ1: 0.52, 95% CI:
0.24-1.13). No association was observed between urinary enterodiol concentration and
depressive symptoms (ORQ4vsQ1: 0.97, 95% CI: 0.50-1.90 in the multivariable adjusted
model).
Table 4.6 Main Effects in Dichotomous Outcome - Kroenke
For enterolactone, a statistically significant reduced odds of depression was
observed among those in the highest quartile in the simple model. The association
remained statistically significant in the adjusted model for both quartile 3 and quartile 4
as compared to quartile 1 (ORQ3vsQ1: 0.53, 95% CI: 0.30-0.95; ORQ4vsQ1: 0.29, 95% CI:
0.14-0.60).
While not statistically significant in either the simple or adjusted model, a modest
inverse association was observed between enterodiol concentration and depression
(ORQ4vsQ1: 0.79, 95% CI: 0.41-1.54 in the multivariable-adjusted model).
Table 4.7-4.9 Main Effects in Three Level Outcome
When comparing those in the minimal depression group to those in the severe
depression group, a statistically significant inverse association was observed in the simple
model for urinary enterolactone (ORQ4vsQ1: 0.31, 95% CI: 0.10-0.93) which was
attenuated and no longer statistical significant in the multivariable-adjusted model
(ORQ4vsQ1: 0.46, 95% CI: 0.15-1.42). While not statistically significant in either the
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simple of adjusted model, an inverse association was observed between urinary
enterodiol concentration and severe depression (ORQ4vsQ1: 0.56, 95% CI: 0.15-2.12 in the
multivariable adjusted model).
When comparing those in the no depression group to those in the moderate
depression group, a statistically significant inverse association was observed in the simple
model comparing quartile 4 of urinary enterolactone to quartile 1 (ORQ4vsQ1: 0.60, 95%
CI: 0.41-0.87) which was attenuated and no longer statistically significant in the adjusted
model (ORQ4vsQ1: 0.74, 95% CI: 0.48-1.13). For enterodiol, no association was observed
with depressive symptoms (ORQ4vsQ1: 1.09, 95% CI: 0.69-1.74 in the multivariable
adjusted model).
When comparing those in the moderate depression group to those in the severe
depression group, inverse associations were observed for both urinary enterolactone and
enterodiol, though CIs were imprecise (enterolactone: ORQ4vsQ1: 0.67, 95% CI: 0.23-1.92;
enterodiol: ORQ4vsQ1: 0.66, 95% CI: 0.19-2.26).
Table 4.10-4.14 Effect Modification by Gender, Smoking Status, BMI, Age, Race
For all stratified analyses, we utilized the dichotomous outcome variable created
using the Kroenke method because the strongest main effects were observed for that
outcome. When stratified by gender, inverse associations between urinary enterolactone
and depressive symptoms were observed in both males and females (males: ORQ4vsQ1:
0.24, 95% CI: 0.07-0.80; females: ORQ4vsQ1: 0.27, 95% CI: 0.13-0.59). No substantial
associations were observed for urinary enterodiol in males or females.
Inverse associations between urinary enterolactone and depressive symptoms
were observed across all strata of smoking status, though associations were strongest
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among former and current smokers (p-trend 0.07 for non-smokers, 0.03 for former
smokers, and 0.02 for current smokers). For urinary enterodiol, associations were
strongest among former smokers, though confidence intervals were wide and there was
no clear trend among any category of smoking status.
When stratifying by BMI, an inverse association between urinary enterolactone
concentration and depressive symptoms was observed across all categories of obesity
status, though strongest associations were observed among overweight participants
(ORQ4vsQ1 0.09, 95% CI: 0.03-0.31). For enterodiol, no clear trends in associations were
observed among strata of obesity status, and confidence intervals tended to be wide,
indicating imprecision of the estimates.
Age group did not substantially modify the inverse association of enterolactone
concentration and depressive symptoms. For those who were 65 and older the inverse
association of enterodiol concentration and depressive symptoms is present in all three
upper quartiles (ORQ2vsQ1 0.13, 95% CI: 0.02-1.06; ORQ3vsQ1 0.31, 95% CI: 0.06-1.60; and
ORQ4vsQ1 0.19, 95% CI: 0.03-1.19).
When stratifying by race, an inverse association between urinary enterolactone
concentration and depressive symptoms was observed among all race/ethnicity groups
across all quartiles except for Quartile 3 in the Other race group (ORQ3vsQ1 1.40, 95% CI:
0.23-8.43). The confidence interval was wide likely due to the small sample size. An
inverse association between urinary enterodiol concentration and depressive symptoms
for Black and Mexican American race groups was observed but no clear trends in
associations were observed among White or Other race participants and confidence
intervals tended to be wide, indicating imprecision of the estimates.
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Figure 4.1 Exclusion Flowchart
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Table 4.1 Creatinine Adjusted Urinary Enterolignan and Demographic Characteristics of NHANES
Participants by PHQ-9 (3 Level Outcome Variable)

Enterolignans, mean
(SD)
(creatinine adjusted)
Enterolactone (µg/g)
Enterodiol (µg/g)
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Gender, n (%)
Male
Female
Age, mean (SD)
BMI, n (%)
Underweight
Normal
Overweight
Obese
Race/Ethnicity, n (%)
White
Black
Mexican American
Other
Education, n (%)
Less than 9th grade
9-11 grade

Overall
N=1933

Minimal
N=1314

Mild/Moderate
N=554

Moderately
Severe/Severe
N=65

880.19
(79.79)
174.50
(21.20)

973.71 (98.25)
188.30 (27.57)

662.50 (97.93)
145.74 (19.26)

396.46 (35.43)
71.12 (12.18)

882 (46)
1051 (54)

643 (49)
671 (51)

221 (40)
333 (60)

18 (28)
47 (72)

44.26 (0.63)

44.82 (0.75)

42.66 (1.09)

44.34 (1.42)

27 (1)
563 (29)
620 (32)
723 (38)

17 (1)
391 (30)
435 (33)
471 (36)

9 (2)
156 (28)
167 (30)
222 (40)

1 (1)
16 (25)
18 (28)
30 (46)

986 (51)
360 (19)
354 (18)
233 (12)

702 (53)
245 (19)
220 (17)
147 (11)

253 (46)
99 (18)
122 (22)
80 (14)

31 (48)
16 (25)
12 (18)
6 (9)

178 (9)
293 (15)

103 (8)
172 (13)

62 (11)
113 (21)

13 (20)
8 (12)
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Highschool
Some college
College +
Marital Status, n (%)
Single
Married
Widowed
Separated/Divorced
PIR Category, n (%)
<1
2-4
5+
Smoking Status, n
(%)
Never Smoker
Ex Smoker
<10 yrs quit
>10 yrs quit
Current Smoker
Pack years
0-10
11-20
>20
Alcohol
Avg drinks per day, n
(%)
0-5
6+

477 (25)
568 (29)
417 (22)

321 (24)
380 (29)
338 (26)

140 (25)
166 (30)
73 (13)

16 (25)
22 (34)
6 (9)

368 (19)
1171 (60)
128 (7)
266 (14)

242 (18)
839 (64)
83 (7)
150 (11)

115 (21)
307 (55)
40 (7)
92 (17)

11 (17)
25 (38)
5 (8)
24 (37)

399 (21)
1150 (59)
384 (20)

229 (18)
779 (59)
306 (23)

144 (26)
336 (61)
74 (13)

26 (40)
35 (54)
4 (6)

1037 (54)

727 (55)

285 (51)

25 (38)

199 (10)
258 (14)

137 (10)
196 (15)

51 (9)
58 (11)

11 (17)
4 (6)

217 (11)
81 (4)
141 (7)

121 (9)
45 (4)
88 (7)

86 (16)
33 (6)
41 (7)

10 (15)
3 (5)
12 (19)

1717 (89)
216 (11)

1177 (90)
137 (10)

479 (86)
75 (14)

61 (94)
4 (6)

Table 4.2 Creatinine Adjusted Urinary Enterolignan and Demographic Characteristics of NHANES
Participants by PHQ-9 (2 Level Outcome Using Pfizer Method)

Enterolignans, mean
(SD)
(creatinine adjusted)
Enterolactone (µg/g)
Enterodiol (µg/g)
Gender, n (%)
Male
Female
Age, mean (SD)
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BMI, n (%)
Underweight
Normal
Overweight
Obese
Race/Ethnicity, n (%)
White
Black
Mexican American
Other
Education, n (%)
Less than 9th grade
9-11 grade
Highschool
Some college
College +

Overall
N=1933

Not Depressed
N=1712

Depressed
N=221

880.19 (79.79)
174.50 (21.20)

918.93 (85.14)
175.04 (22.18)

468.47 (50.43)
168.71 (65.01)

882 (46)
1051 (54)

794 (46)
918 (54)

88 (40)
133 (60)

44.26 (0.63)

44.23 (0.70)

44.10 (0.91)

27 (1)
563 (29)
620 (32)
723 (38)

23 (1)
510 (30)
549 (32)
630 (37)

4 (2)
53 (24)
71 (32)
93 (42)

986 (51)
360 (19)
354 (18)
233 (12)

909 (53)
302 (18)
299 (17)
202 (12)

77 (35)
58 (26)
55 (25)
31 (14)

178 (9)
293 (15)
477 (25)
568 (29)
417 (22)

139 (8)
248 (14)
423 (25)
506 (30)
396 (23)

39 (18)
45 (20)
54 (24)
62 (28)
21 (10)
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Marital Status, n (%)
Single
Married
Widowed
Separated/Divorced
PIR Category, n (%)
<1
2-4
5+
Smoking Status, n (%)
Never Smoker
Ex Smoker
<10 yrs quit
>10 yrs quit
Current Smoker
Pack years
0-10
11-20
>20
Alcohol
Avg drinks per day, n
(%)
0-5
6+

368 (19)
1171 (60)
128 (7)
266 (14)

320 (19)
1063 (62)
112 (6)
217 (13)

48 (22)
108 (49)
16 (7)
49 (22)

399 (21)
1150 (59)
384 (20)

329 (19)
1023 (60)
360 (21)

70 (32)
127 (57)
24 (11)

1037 (54)

927 (54)

110 (50)

199 (10)
258 (14)

177 (10)
235 (14)

22 (10)
23 (11)

217 (11)
81 (4)
141 (7)

185 (11)
70 (4)
118 (7)

32 (14)
11 (5)
23 (10)

1717 (89)
216 (11)

1523 (89)
189 (11)

194 (88)
27 (12)

Table 4.3 Creatinine Adjusted Urinary Enterolignan and Demographic Characteristics of NHANES Participants by
PHQ-9 (2 Level Outcome Using Kroenke Method)

Enterolignans, mean (SD)
(creatinine adjusted)
Enterolactone (µg/g)
Enterodiol (µg/g)
Gender, n (%)
Male
Female
Age, mean (SD)
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BMI, n (%)
Underweight
Normal
Overweight
Obese
Race/Ethnicity, n (%)
White
Black
Mexican American
Other
Education, n (%)
Less than 9th grade
9-11 grade
Highschool
Some college
College +

Overall
N=1933

Not Depressed
N=1739

Depressed
N=194

880.19 (79.79)
174.50 (21.20)

921.80 (83.17)
182.59 (22.36)

365.52 (41.86)
74.42 (8.20)

882 (46)
1051 (54)

832 (48)
907 (52)

50 (26)
144 (74)

44.26 (0.63)

44.30 (0.68)

44.30 (0.68)

27 (1)
563 (29)
620 (32)
723 (38)

24 (1)
506 (29)
563 (33)
646 (37)

3 (2)
57 (29)
57 (29)
77 (40)

986 (51)
360 (19)
354 (18)
233 (12)

909 (52)
318 (18)
310 (18)
202 (12)

77 (40)
42 (21)
44 (23)
31 (16)

178 (9)
293 (15)
477 (25)
568 (29)
417 (22)

150 (9)
250 (14)
429 (25)
510 (29)
400 (23)

28 (14)
43 (22)
48 (25)
58 (30)
17 (9)

Marital Status, n (%)
Single
Married
Widow
Separated/Divorced
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PIR Category, n (%)
<1
2-4
5+
Smoking Status, n (%)
Never Smoker
Ex Smoker
<10 yrs quit
>10 yrs quit
Current Smoker
Pack years
0-10
11-20
>20
Alcohol
Avg drinks per day, n (%)
0-5
6+

368 (19)
1171 (60)
128 (7)
266 (14)

330 (19)
1081 (62)
112 (7)
216 (12)

38 (20)
90 (46)
16 (8)
50 (26)

399 (21)
1150 (59)
384 (20)

324 (19)
1043 (60)
372 (21)

75 (39)
107 (55)
12 (6)

1037 (54)

950 (55)

87 (45)

199 (10)
258 (14)

178 (10)
244 (14)

21 (11)
14 (7)

217 (11)
81 (4)
141 (7)

183 (10)
69 (4)
115 (7)

34 (18)
12 (6)
26 (13)

1717 (89)
216 (11)

1546 (89)
193 (11)

171 (88)
23 (12)

Table 4.4 Creatinine Adjusted Urinary Enterolignan Cut-points Based on Non- or
Minimally-Depressed Population
1st Quartile
Overall

2nd Quartile

3rd Quartile

4th
Quartile
>903.39
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Enterolactone

<89.43

89.43-336.38

Enterodiol

<17.18

17.18-46.45

336.39903.39
46.46-115.18

Minimal
Depression
(three level)

Enterolactone

<105.12
<17.50

355.97972.76
47.37-119.94

>972.76

Enterodiol

105.12355.96
17.50-47.36

No Depression
(dichotomous
Pfizer)

Enterolactone

<95.88

95.88-344.43

>928.19

Enterodiol

<17.26

17.26-46.91

344.44928.19
46.92-117.98

No depression
(dichotomous
Kroenke)

Enterolactone

<98.32

98.32-349.29

>941.76

Enterodiol

<17.30

17.30-46.77

349.30941.76
46.78-118.05

>117.18

>119.94

>117.98

>118.05

Table 4.5 Association between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (2 Level Outcome Using Pfizer Method)

N,
depressed/non
depressed cases
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Enterolactone (µg/g)
creatinine quartiles
≤ 95.87
95.88-344.43

78/404
51/429

344.44-928.19

56/450

> 928.19

36/429

Ptrend

Adjusted Modelb
OR,
95% CI

0.003

Enterodiol (µg/g)
creatinine quartiles
≤ 17.25
17.26-46.91

68/440
65/443

46.92-117.98

47/424

> 117.98

41/405

a

Simple Modela
OR,
95% CI

Ref
0.65
(0.36-1.19)
0.60
(0.32-1.12)
0.39
(0.19-1.02)

0.02
Ref
0.69
(0.36-1.32)
0.70
(0.37-1.33)
0.52
(0.24-1.13)

0.90
Ref
0.94
(0.55-1.58)
0.84
(0.42-1.59)
0.70
(0.40-1.22)

0.66
Ref
1.06
(0.59-1.91)
1.04
(0.51-2.12)
0.97
(0.50-1.90)

Adjusted for age
Additionally adjusted for BMI, alcohol intake, PIR, marital status, race, education, smoking status, gender

b

Ptrend

Table 4.6 Association between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (2 Level Outcome Using Kroenke Method)

N,
depressed/non
depressed
cases

44

Enterolactone (µg/g)
creatinine quartiles
≤ 98.31
98.32-349.29

70/418
48/431

349.30-941.76

52/454

> 941.76

24/436

Ptrend

Adjusted Modelb
OR
95% CI

0.0003

Enterodiol (µg/g)
creatinine quartiles
≤ 17.29
17.30-46.77

62/447
50/453

46.78-118.05

45/431

> 118.05

37/408

a

Simple Modela
OR
95% CI

Ref
0.55
(0.31-0.99)
0.48
(0.28-0.84)
0.23
(0.11-0.47)

0.001
Ref
0.55
(0.29-1.04)
0.53
(0.30-0.95)
0.29
(0.14-0.60)

0.004
Ref
0.78
(0.45-1.37)
0.81
(0.40-1.63)
0.62
(0.36-1.05)

0.06
Ref
0.87
(0.47-1.57)
0.93
(0.43-2.01)
0.79
(0.41-1.54)

Adjusted for age
Additionally adjusted for BMI, alcohol intake, PIR, marital status, race, education, smoking status, gender

b

Ptrend

Table 4.7 Association between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (3 Level Outcome – No Depression vs Severe)

N, severe/none
Enterolactone (µg/g)
creatinine quartiles
≤ 105.11
105.12-355.96

23/313
16/328

355.97-972.76

17/346

> 972.76

9/327

Ptrend

Adjusted Modelb
OR,
95% CI

0.01
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Enterodiol (µg/g)
creatinine quartiles
≤ 17.49
17.50-47.36

18/334
22/340

47.37-119.94

15/326

> 119.94

10/314

a

Simple Modela
OR,
95% CI

Ref
0.50
(0.20-1.26)
0.46
(0.20-1.10)
0.31
(0.10-0.93)

0.03
Ref
0.61
(0.22-1.72)
0.61
(0.25-1.45)
0.46
(0.15-1.42)

0.15
Ref
1.10
(0.43-2.79)
0.73
(0.26-2.05)
0.49
(0.98-1.02)

0.31
Ref
1.35
(0.46-3.99)
0.94
(0.34-2.65)
0.56
(0.15-2.12)

Adjusted for age
Additionally adjusted for BMI, alcohol intake, PIR, marital status, race, education, smoking status, gender

b

Ptrend

Table 4.8 Association between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (3 Level Outcome – No Depression vs Moderate)
Simple Modela
N,
OR,
moderate/none 95% CI
Enterolactone (µg/g)
creatinine quartiles
≤ 105.11
105.12-355.96

172/313
125/328

355.97-972.76

151/346

> 972.76

106/327

0.17

46
Enterodiol (µg/g)
creatinine quartiles
≤ 17.49
17.50-47.36

163/334
146/340

47.37-119.94

130/326

> 119.94

115/314

a

Ptrend

Adjusted Modelb
OR,
95% CI

Ref
0.71
(0.46-1.10)
0.83
(0.59-1.16)
0.60
(0.41-0.87)

0.40
Ref
0.75
(0.49-1.15)
0.95
(0.67-1.35)
0.74
(0.48-1.13)

0.40
Ref
1.07
(0.77-1.49)
1.07
(0.77-1.49)
1.12
(0.72-1.72)

0.83
Ref
1.02
(0.73-1.42)
1.06
(0.73-1.54)
1.09
(0.69-1.74)

Adjusted for age
Additionally adjusted for BMI, alcohol intake, PIR, marital status, race, education, smoking status, gender

b

Ptrend

Table 4.9 Association between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (3 Level Outcome– Moderate vs. Severe)

N,
severe/moder
ate
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Enterolactone (µg/g)
creatinine quartiles
≤ 105.11
105.12-355.96

23/172
16/125

355.97-972.76

17/151

> 972.76

9/106

Ptrend

Adjusted Modelb
OR,
95% CI

0.08

Enterodiol (µg/g)
creatinine quartiles
≤ 17.49
17.50-47.36

18/163
22/146

47.37-119.94

15/130

> 119.94

10/115

a

Simple Modela
OR,
95% CI

Ref
0.85
(0.31-2.33)
0.60
(0.25-1.41)
0.52
(0.16-1.74)

0.08
Ref
0.78
(0.30-2.04)
0.64
(0.24-1.65)
0.67
(0.23-1.92)

0.15
Ref
1.19
(0.49-2.89)
0.86
(0.31-2.38)
0.52
(0.19-1.43)

0.44
Ref
1.21
(0.50-2.89)
0.93
(0.34-2.61)
0.66
(0.19-2.26)

Adjusted for age
Additionally adjusted for BMI, alcohol intake, PIR, marital status, race, education, smoking status, gender

b

Ptrend

Table 4.10 Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by Gender
Male
N,
OR,
depressed/non 95% CI
depressed
cases

48

Enterolactone
(µg/g) creatinine
quartiles
≤ 105.11
105.12-355.96

21/242
11/216

355.97-972.76

15/205

> 972.76

3/169

Enterodiol (µg/g)
creatinine
quartiles
≤ 17.49
17.50-47.36

Ptrend

Female
N,
OR,
depressed/non 95% CI
depressed
cases

0.04

Ref
0.60
(0.17-2.05)
0.86
(0.31-2.37)
0.24
(0.07-0.80)

0.01

49/176
37/215
37/249
21/267

Ref
0.53
(0.29-0.94)
0.46
(0.24-0.90)
0.27
(0.13-0.59)

0.36

18/264
15/229

Ptrend

Ref
44/183
Ref
0.96
35/224
0.85
(0.35-2.60)
(0.44-1.66)
47.37-119.94
10/201
0.92
35/230
0.89
(0.27-3.17)
(0.42-1.88)
> 119.94
7/138
1.05
30/270
0.79
(0.28-3.93)
(0.38-1.65)
a
Adjusted for age, BMI, alcohol intake, PIR, marital status, race, education, smoking status

0.09

Table 4.11 Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by Smoking Status

N,
depressed
/non
depressed
cases
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Enterolactone (µg/g)
creatinine quartiles
≤ 98.31

25/193

98.32-349.29

21/243

349.30-941.76

28/255

> 941.76

13/259

Enterodiol (µg/g)
creatinine quartiles
≤ 17.29

Never
OR
95% CI

Ptrend

N,
depressed
/non
depressed
cases

Former
OR
95% CI

0.07
1
Ref
0.63
0.28-1.43
0.67
0.29-1.53
0.47
0.16-1.35

N,
depressed
/non
depressed
cases

0.03
12/91
10/83
7/120
6/128

1
Ref
0.68
0.24-1.87
0.14
0.05-0.44
0.13
0.03-0.46

0.12
24/232

Ptrend

Current
OR
95% CI

1
9/83
1
Ref
Ref
17.30-46.77
24/239
0.81
8/115
0.39
0.35-1.89
0.08-1.83
46.78-118.05
19/234
0.64
8/110
1.19
0.28-1.46
0.25-5.75
> 118.05
20/245
0.94
10/114
0.33
0.41-2.19
0.08-1.38
a
Adjusted for age, BMI, alcohol intake, PIR, marital status, race, education, gender

Ptrend

0.02
33/134
17/105
17/79
5/49

1
Ref
0.43
0.17-1.12
0.79
0.33-1.87
0.16
0.04-0.68

0.23

0.34
29/132
18/99
18/87
7/49

1
Ref
1.20
0.48-3.00
0.95
0.28-3.25
0.87
0.21-3.61

Table 4.12 Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol (Quartiles) and
Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by BMI

N,
depressed
/non
depressed
cases

50

Enterolactone
(µg/g) creatinine
quartiles
≤ 98.31
98.32-349.29

20/108
12/112

349.30-941.76

16/140

> 941.76

9/146

Enterodiol (µg/g)
creatinine
quartiles
≤ 17.29
17.30-46.77

Normal
OR.
95% CI

Ptrend

N,
depressed
/non
depressed
cases

Overweight
OR,
Ptrend
95% CI

0.05

Ref
0.53
(0.20-1.40)
0.62
(0.28-1.37)
0.39
(0.13-1.15)

15/127
118/99

0.02

22/115
14/139
13/147
8/162
0.07

N,
depressed
/non
depressed
cases

Obese
OR
95% CI

Ref
0.42
(0.17-1.03)
0.35
(0.10-1.26)
0.09
(0.03-0.31)

0.23

27/192
21/174
23/160
6/120

Ref
0.78
0.28-2.17
0.66
0.24-1.78
0.41
0.10-1.74

0.12

Ref
17/143
Ref
1.44
12/147
0.45
(0.50-4.12)
(0.15-1.34)
46.78-118.05
15/131
1.02
14/134
1.35
(0.32-3.32)
(0.48-3.79)
> 118.05
9/149
0.38
14/139
0.73
(0.14-1.09)
(0.30-1.76)
a
Adjusted for age, alcohol intake, PIR, marital status, race, education, gender, smoking status

Ptrend

0.52

28/172
19/202
16/159
14/113

Ref
0.72
(0.29-1.77)
0.69
(0.21-2.29)
1.53
(0.43-5.47)

Table 4.13 Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol (Quartiles) and
Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by Age
20-45
N,
depressed
/non
depressed
cases
Enterolactone (µg/g)
creatinine quartiles
≤ 98.31
44/248
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98.32-349.29

28/267

349.30-941.76

24/227

> 941.76

6/164

Enterodiol (µg/g)
creatinine quartiles
≤ 17.29

37/272

17.30-46.77

29/236

OR
95% CI

46-65
Ptren
d

N,
depressed
/non
depressed
cases

OR
95% CI

0.13

65+
Ptrend

N,
depressed
/non
depressed
cases

OR
95% CI

0.01

0.04

Ref

22/128

Ref

4/42

Ref

0.54
(0.25-1.19)
0.57
(0.28-1.19)
0.23
(0.05-1.02)

16/121

0.49
(0.18-1.34)
0.42
(0.17-1.03)
0.31
(0.11-0.84)

4/43

0.76
(0.12-4.69)
0.47
(0.06-3.49)
0.17
(0.03-1.05)

21/135
13/156
0.32

Ref

7/92
5/116
0.16

19/122

Ref

1.03
18/147
0.65
(0.54-1.96)
(0.23-1.84)
46.78-118.05
24/225
1.23
15/132
0.57
(0.47-3.19)
(0.20-1.64)
> 118.05
12/173
0.80
20/139
0.87
(0.28-2.30)
(0.28-2.70)
a
Adjusted for BMI, alcohol intake, PIR, marital status, race, education, gender, smoking status

Ptrend

0.30
6/53

Ref

3/70

0.13
(0.02-1.06)
0.31
(0.06-1.60)
0.19
(0.03-1.19)

6/74
5/96

Table 4.14a Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol
(Quartiles) and Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by Race- White/Black
White
N, depressed/non
depressed cases
Enterolactone (µg/g)
creatinine quartiles
≤ 98.31
33/210
98.32-349.29
17/204
349.30-941.76

19/233

> 941.76

8/262
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Enterodiol (µg/g)
creatinine quartiles
≤ 17.29

21/191

17.30-46.77

21/225

OR,
95% CI

Black
Ptrend

N, depressed/non
depressed cases

OR,
95% CI

0.02
Ref
0.45
(0.16-1.24)
0.42
1.18-0.98
0.19
(0.06-0.57)

0.36
18/87
10/91
10/91
4/49

Ref
0.48
(0.17-1.33)
0.64
(0.26-1.57)
0.30
(0.07-1.27)

0.26
Ref

Ptrend

0.57
16/110

0.73
13/96
(0.17-3.19)
46.78-118.05
23/242
1.56
6/65
(0.35-7.08)
> 118.05
12/251
1.07
7/47
(0.32-3.57)
a
Adjusted for age, BMI, alcohol intake, PIR, marital status, education, gender, smoking status

Ref
0.78
(0.28-2.18)
0.64
(0.20-2.05)
0.65
(0.18-2.31)

Table 4.14b Associationa between Creatinine Adjusted Urinary Concentrations of Enterolactone and Enterodiol (Quartiles)
and Depressive Symptoms (2 Level Outcome Using Kroenke Method) Stratified by Race- Mexican American/Other
Mexican American
N, depressed/non
depressed cases
Enterolactone
(µg/g)
creatinine
quartiles
≤ 98.31
10/63
98.32-349.29
14/83
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349.30-941.76

15/85

> 941.76

5/79

Enterodiol
(µg/g)
creatinine
quartiles
≤ 17.29

17/87

17.30-46.77

12/89

OR,
95% CI

Other
Ptrend

N, depressed/non
depressed cases

OR,
95% CI

0.01

Ref
1.32
0.52-3.35
0.81
0.26-2.61
0.20
0.04-1.15

0.38

9/58
7/53
8/45
7/46

Ref
0.67
0.13-3.48
1.40
0.23-8.43
0.62
0.12-3.20

0.39

Ref

Ptrend

0.10

8/59

0.68
4/43
0.29-1.58
46.78-118.05
9/78
0.58
7/46
0.17-1.92
> 118.05
6/56
0.48
12/54
0.13-1.83
a
Adjusted for age, BMI, alcohol intake, PIR, marital status, education, gender, smoking status

Ref
0.73
0.17-3.19
1.56
0.34-7.08
1.07
0.32-3.57

CHAPTER 5
DISCUSSION
Summary and Significance of Results
This study examined the association between urinary enterolignans as a marker
for gut microbiome diversity and depressive symptoms using NHANES data. The study
found that participants in the highest enterolactone quartile were less likely to be
experiencing depressive symptoms compared to those in the lowest quartile. While
associations between depressive symptoms and urinary enterodiol were also generally
inverse, the effect estimates were weaker and none of the trend tests were statistically
significant. Given that urinary enterolactone, but not urinary enterodiol, has been
associated with gut microbiota diversity (Hullar et al., 2014), our results support the
hypothesis that higher gut microbiota diversity is linked to reduced odds of depressive
symptoms.
The outcome variable, depressive symptoms, was scored using three different
methods. Using the Pfizer scoring method, a two-level and a three-level outcome variable
were produced. Using the Kroenke method, another two-level outcome was created.
Exposure variables were categorized by using quartiles determined by distribution of
enterolignan concentration for the non-depressed groups. While the dichotomous
outcome using the Kroenke method was the only outcome that resulted in statistically
significant reduced odds of depressive symptoms among those in the higher enterolignan
quartiles, all outcome variable methods produced odds ratios that reflected an inverse
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relationship. In our three-level outcome analyses the association could be attenuated as a
result of dividing the already small depressed population into multiple groups. For the
Pfizer method, the extra criteria of having to mark either question 1 or 2 as “more than
half the days”, while an important marker of depression, may have categorized those with
high PHQ-9 scores as not depressed incorrectly because they did not meet that criteria. In
contrast, there are less participants classified as depressed in the Kroenke method
(n=194) compare to the Pfizer method (n=221). This could be due to an increased number
of false positives in the Pfizer method as the overall score needed to be considered
depressed (overall score as low as 4) is less than the score Kroenke uses (score of 10 or
more). Misclassification of the outcome may have attenuated the results.
Urinary enterolactone showed the most notable inverse relationship to depressive
symptoms as associations were stronger and more results were statistically significant as
compared to enterodiol. Differences in the effects of the two metabolites could be related
to differences in location along the metabolic pathway. Enterolactone is one step further
in the lignan metabolism pathway than enterodiol which suggests that the later steps may
be more involved with a depressed-associated microbial environment (Frankenfeld et al.,
2013). Enterodiol has a mean elimination half-life and mean residence time much smaller
than enterolactone (Kujsten et al, 2005). It is also worth noting that on average, urine
samples consisted of a smaller quantity of enterodiol compared to enterolactone. This
observation was corroborated in another study looking at the absorption and excretion of
enterolignans which found that the majority of enterolignans excreted via urine was
enterolactone at 58% (Kujsten et al., 2005). Smaller variability in urinary enterodiol
concentrations (as compared to urinary enterolactone) may have inhibited our ability to
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detect a significant difference between depressive categories, and as noted previously,
urinary enterodiol was not associated with gut microbiome diversity in a previous study
(Hullar et al., 2014).
The associations between enterolignans and depressive symptoms using the
Kroenke outcome method for classifying depressive symptoms were not modified
substantially by gender, smoking status, obesity status, age, or race with the exception
that strong inverse associations were observed for urinary enterodiol among participants
aged 65 or older which were not observed in other age groups. Confidence intervals were
wide given the small number of individuals with depressive symptoms among the older
study population, and we cannot rule out the role of chance in this finding. Furthermore,
when stratified by race, an inverse association between urinary enterodiol concentration
and depressive symptoms was observed for Black and Mexican American participants
but not for White or Other race participants. Confidence intervals tended to be wide in
these associations as well, indicating imprecision of the estimates. It is difficult to draw
any major conclusions from the results given that the population size for those
categorized as having depressive symptoms is small and stratifying even further often
resulted in unstable effect estimates.
Overall, our results align with our hypothesis that increased urinary enterolactone
(signifying an increased gut microbiome diversity) is inversely associated with depressive
symptoms. Circulating enterolignan levels have been positively associated with dietary
fiber, diets low in fat and rich in fruits and vegetables (Lampe et al., 1999, Stumpf et al,
2000). These findings align with previous studies that have been conducted using both
human and rodent models showing that the gut microbiome of depressed patients is
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significantly different from that of healthy controls (Kelly et.al, 2016 Zheng et al, 2016).
In one study, microbiota diversity and richness was lower in depressed patients in
comparison to healthy controls using fecal microbiota as a marker (Kelly et. al, 2016). In
another study, fecal samples collected from depressed and nondepressed individuals
showed depressed individuals had less Bacteroidetes than those without depression
(Zheng et al., 2016). Through colonic fermentation, Bacteroidetes in the gut produce
butyrate which can have antineoplastic properties and could play a role in maintaining a
healthy gut (Kim and Milner, 2007). Other studies show that a reduced abundance of
Bacteroidetes is a characteristic of obesity in both human and animal models (Petriz et
al., 2014, Duca et al., 2014).
Microbiota are believed to affect depressive symptoms through the gut-brain axis.
Among 655 adults aged 18 and older, fecal samples and questionnaire data revealed that
higher anxiety and stress scores were linked to a decreased diversity of gut bacteria
(Johnson, 2019). Research has shown that a healthy gut supports normal central nervous
system function (Daulatzai, 2015). The gut-brain axis is the bidirectional communication
between the gut microbiota and the central nervous system (Clapp et al., 2017). When
there is dysbiosis, a common result of reduced gut microbiome diversity, there is more
intestinal permeability, which allows inflammatory cytokines to travel systemically
through the body. A higher of concentration of these cytokines in the blood creates a
permeability in the blood brain barrier which allows these inflammatory cytokines to
influence the brain (Gadek et al, 2013). Brain function is then altered which could result
in symptoms of anxiety and depression (Gadek et al. 2013, Biesman et al, 2015). Our
research study provides support for the hypothesis that gut microbiome dysbiosis could
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contribute to depressive symptoms. Our findings support other studies that have
suggested that reduced diversity or depletion of gut microbiome bacteria can induce
inflammatory responses that can be associated with various mental health disorders such
as depression (Berk et al., 2013). Prior research has suggested that mental illnesses are
not just caused by psychological stressors but also inflammatory conditions that could be
rooted in our gut (Berk et al., 2013).
If corroborated in additional studies, our findings may lend support to intervention
studies aimed at altering the gut microbiota composition, such as through probiotics, as
one option for improving psychological symptoms. One study found that administering
probiotic bacteria can modulate brain activity in humans confirming the link between the
gut microbiota and brain (Tillisch et al., 2013). In a rodent study, mice who were
administered certain strains of probiotics demonstrated a reduced number of anxietyrelated behaviors compared to mice not given the probiotics (Matthews et al., 2013).
Thus, altering the gut microbiota through probiotics or other dietary modifications to
beneficially affect depressive symptoms is an area in need of future research.
Strengths and Limitations
NHANES collects data from a nationally representative population which
provides a diverse group of participants, a large sample size, and external validity. The
data collected from NHANES questionnaires and laboratory data were comprehensive
which allowed for a variety of covariates to be included to adjust for potential
confounding. As one of the few studies in humans on gut microbiome diversity and
depressive symptoms, the study advances the field and provides more evidence for
potential therapeutic approaches related to gut microbiota manipulation.
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A few limitations should be noted. While NHANES provided a large
comprehensive sample of participants, it is a cross sectional design so temporality of the
exposure-outcome relationship cannot be established, and reverse causality is a
possibility. We utilized a one-time measurement of urinary enterolignans and previous
studies have shown dose-dependent increases in urinary enterolignans in as little as 24
hours after consuming the precursor lignans (Kuijsten et al., 2005) with large variability
between individuals which may be explained by inter-individual differences in
microbiota diversity (Hutchins et al., 2000). Thus, more research is needed to determine
is averaging multiple urinary measurements over time to reduce the day-to-day variability
would provide more accurate estimates of gut microbiota diversity. While enterolignans
are an established marker of gut microbiome diversity, it is still a limitation that this
study is not using a more direct measurement of gut microbiome diversity such as
through metagenomics of fecal samples (Hullar et al. 2014, Shivappa et al, 2019,
Frankenfeld et al., 2013). The PHQ-9 is a widely used instrument for measuring
depressive symptoms, but it is not a clinical diagnosis. Using PHQ-9 could result in either
an over report of depressive symptoms or under report of depressive symptoms as a
licensed professional does not verify the diagnosis and the questionnaire reflects
participants symptoms within the past two weeks only. To include all the covariates of
interest in the analysis, our age group consisted of those 20 or older. These findings can
therefore not be generalizable to the youth of America. While we were able to control for
several medications and medical conditions, we may have missed some unknown or
unprovided information that could affect gut diversity or mental health and could bias our
results.
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Recommendations for Future Research
This study found inverse associations between urinary enterolactone
concentration and the odds of elevated depressive symptoms scoring. Urinary
enterolactone is a marker for gut microbiome diversity. The results of the study provide
support for the hypothesis that gut microbiome diversity is inversely related to depressive
symptoms and provides justification to conduct future studies using more direct methods
of measuring gut microbiome diversity and its association with depression. If feasible,
using a more accurate or clinically verified method for diagnosing depression would be
recommended for future studies instead of using PHQ-9. A prospective study design
would be recommended in order to establish the temporal relationship between gut
microbiome diversity and depressive symptoms. Clinical relevance could be found by
identifying a diet that supports gut health which could be used as a template for those
trying to manage depressive symptoms. Also identifying specific strains of bacteria
associated with improved depressive scoring could help further advance the clinical
relevance of this area of research.
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